S

Samil Pharmaceutical Co Ltd
KRX:000520

Watchlist Manager
Samil Pharmaceutical Co Ltd
KRX:000520
Watchlist
Price: 10 570 KRW -1.12% Market Closed
Market Cap: 229.3B KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+40%
Revenue
Forecast
+16%
Operating Income
Forecast
+417%
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
Samil Pharmaceutical Co Ltd

Wall Street analysts forecast Samil Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Samil Pharmaceutical Co Ltd is 14 790 KRW with a low forecast of 14 645 KRW and a high forecast of 15 225 KRW.

Lowest Forecast
Wall Street Target
14 645 KRW
39% Upside
Average Forecast
Wall Street Target
14 790 KRW
40% Upside
Highest Forecast
Wall Street Target
15 225 KRW
44% Upside
Lowest
Price Target
14 645 KRW
39% Upside
Average
Price Target
14 790 KRW
40% Upside
Highest
Price Target
15 225 KRW
44% Upside
Samil Pharmaceutical Co Ltd Competitors:
Price Targets
LINCOLN
Lincoln Pharmaceuticals Ltd
85% Upside
T
TRUL
Trulieve Cannabis Corp
72% Upside
H
293480
Hana Pharm Co Ltd
34% Upside
1795
Lotus Pharmaceutical Co Ltd
32% Upside
LINCOLN
Lincoln Pharmaceuticals Ltd
85% Upside
T
TRUL
Trulieve Cannabis Corp
72% Upside
H
293480
Hana Pharm Co Ltd
34% Upside
1795
Lotus Pharmaceutical Co Ltd
32% Upside
LAURUSLABS
Laurus Labs Ltd
20% Downside
CURA
Curaleaf Holdings Inc
6% Upside
C
000661
Changchun High & New Technology Industries Group Inc
2% Downside
U
3933
United Laboratories International Holdings Ltd
21% Upside

Revenue
Forecast

Revenue Estimate
Samil Pharmaceutical Co Ltd

For the last 13 years the compound annual growth rate for Samil Pharmaceutical Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 16%.

7%
Past Growth
16%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Samil Pharmaceutical Co Ltd

The compound annual growth rate of Samil Pharmaceutical Co Ltd's operating income for the next 3 years is 417%.

N/A
Past Growth
417%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Samil Pharmaceutical Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Samil Pharmaceutical Co Ltd's stock price target?
Price Target
14 790 KRW

According to Wall Street analysts, the average 1-year price target for Samil Pharmaceutical Co Ltd is 14 790 KRW with a low forecast of 14 645 KRW and a high forecast of 15 225 KRW.

What is Samil Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
16%

For the last 13 years the compound annual growth rate for Samil Pharmaceutical Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 16%.

What is Samil Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
417%

The compound annual growth rate of Samil Pharmaceutical Co Ltd's operating income for the next 3 years is 417%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 283,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.